Navigation Links
Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Date:8/19/2007

Company on Target to File Supplemental New Drug Application in the Fourth

Quarter

FRAZER, Pa., Aug. 16 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced positive results from a 12-week, Phase 3 clinical trial of FENTORA(R) (fentanyl buccal tablet) [C-II] in patients with breakthrough pain associated with a broad range of chronic non-cancer pain conditions. The study achieved statistical significance on the primary endpoint. Results across the 12 weeks of treatment showed both statistically significant and clinically relevant outcomes for patients with breakthrough pain who were already receiving and who were tolerant to opioid therapy for their underlying persistent pain. FENTORA is approved only for the management of breakthrough pain in patients with cancer who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

"We are excited to complete our Phase 3 program with this third and final controlled study. These data show similar positive outcomes as those with FENTORA in treating breakthrough pain in opioid-tolerant patients with cancer, chronic neuropathic pain, and chronic low-back pain," said Dr. Lesley Russell, Executive Vice President, Worldwide Medical and Regulatory Operations. "We plan to submit these data to the Food and Drug Administration in the fourth quarter as part of our supplemental New Drug Application."

About the Study

The double-blind, placebo-controlled, variable dose Phase 3 trial included 148 patients. The primary endpoint was the Sum of Pain Intensity Differences from five to 60 minutes (SPID(60)) as assessed after 12 weeks of treatment. SPID(60) is a measure that assesses analgesic efficacy of a pain medication over the first 60 minutes after treatment. Patients treated with FENTORA showed a statistically significant improvement on the primary endpoint (p<0.0001) compared with placebo. FENTORA was general
'/>"/>

SOURCE Cephalon, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5

Related medicine technology :

1. Cephalon Presents Positive Results for Fentora in Breakthrough Pain Associated with Neuropathic Conditions
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Tianyin Pharmaceutical Co., Inc. (NYSE Amex: ... specializes in patented biopharmaceutical, modernized traditional Chinese medicine ... today updates the timeline for the GMP certification ... The Company is scheduled to submit the ... & Drug Administration,s (CFDA) review in the week ...
(Date:8/28/2014)... SALT LAKE CITY , Aug. 28, 2014 /PRNewswire-iReach/ ... in 2000 by service academy graduates, has published a ... its concentrated, three-day Leadership Excellence Course . In ... the  Leadership Excellence Course to Albuquerque , ... Tucson . Photo - http://photos.prnewswire.com/prnh/20140828/140814 ...
(Date:8/28/2014)... Nonin Medical, Inc., the inventor of finger ... today announced that the Food and Drug Administration (FDA) ... oximeter for use in the United States ... telemedicine hub or kiosk through a USB connector and ... adult patients. The Model 3231 received EU certification last ...
Breaking Medicine Technology:TPI Submits Dataset for GMP Inspection at Qionglai Facility (QLF) 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 3Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 4Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 5Nonin Medical Announces FDA Clearance of Nonin Model 3231 USB Pulse Oximeter 2
... Xenogenics Corporation ("Xenogenics"), a majority owned subsidiary of ... to announce it has retained the Emmes Group to ... formation strategy to help finance expanded human clinical trials ... testing and initial human use, the Ideal BioStent™ demonstrated ...
... Biosciences, a privately held company leading the development of ... McDonald, MBA, Senior Vice President and Chief Business Officer, ... will highlight new and innovative cardiovascular drug therapies at ... discussion will be held at the New York Palace ...
Cached Medicine Technology:Xenogenics Corporation Retains the Emmes Group to Advise on Fund Raising Efforts 2Xenogenics Corporation Retains the Emmes Group to Advise on Fund Raising Efforts 3Xenogenics Corporation Retains the Emmes Group to Advise on Fund Raising Efforts 4Regado Biosciences to Present at the 2011 RBC Capital Markets Healthcare Conference in New York City 2Regado Biosciences to Present at the 2011 RBC Capital Markets Healthcare Conference in New York City 3
(Date:8/29/2014)... across the Arabian Peninsula and spread to Europe several ... of several hundred people since its discovery in 2012. ... how easily the pathogen spreads from human to human. ... the University of Bonn have now come to the ... transmission is low. Still, a third of infected persons ...
(Date:8/29/2014)... Glendale Botox experts at Glenoaks Laser Center are ... of September. This special offer features 10 free units of ... can take advantage of this special offer to completely transform ... work with patients to determine if Botox or Juvederm is ... , Botox is a treatment made from the botulinum toxin. ...
(Date:8/29/2014)... VHA Central Atlantic recognized Novant Health ... honoring nine facilities for meeting or exceeding national performance ... Health, providing quality, affordable healthcare for our communities has ... executive vice president and chief medical officer. “These awards ... for each and every one of our patients.” , ...
(Date:8/29/2014)... TX (PRWEB) August 29, 2014 PreDiabetes ... off the fall season by offering Web shoppers a 20% ... PreD Store , the Company’s online healthy living shop, beginning ... should be top priority when heading into the chilly fall ... lifestyle habits. During this season, people usually ditch the healthy ...
(Date:8/29/2014)... August 29, 2014 Many Americans are ... keep diabetes type 2 at bay, patients should consider ... make the necessary lifestyle changes. While some diabetes risk ... history, advanced age, or belonging to certain ethnic groups, ... – their weight. Carrying extra pounds, especially in the ...
Breaking Medicine News(10 mins):Health News:MERS: Low transmissibility, dangerous illness 2Health News:MERS: Low transmissibility, dangerous illness 3Health News:Glenoaks Laser Center is Now Offering a Special Promotion on Botox for the Month of September 2Health News:Novant Health Recognized for Excellence in Clinical Care 2Health News:Novant Health Recognized for Excellence in Clinical Care 3Health News:PreDiabetes Centers Online Store Launches Fall Savings Event 2Health News:Diet Doc Announces Specialized Diet Plans that Help Patients Prevent Diabetes by Stabilizing Blood Sugar Levels and Losing Excess Fat 2Health News:Diet Doc Announces Specialized Diet Plans that Help Patients Prevent Diabetes by Stabilizing Blood Sugar Levels and Losing Excess Fat 3
... has led to the development of proposals to dump about 800 ... end of the month. ,The move follows the ... six months should stay on a list. ,Patients ... within six months are referred back to their GP for monitoring. ...
... have identified key compounds that stimulate stem cell growth ... is set to appear in the September 2006 issue ... one day lead to restored function for people who ... sclerosis, and a wide range of neurological disorders. The ...
... doctors in North Karnataka, cautioned by the health and ... and not to harass them. // ,The ... take action against doctors harassing and denying treatment to ... of the first anniversary celebration of ‘Ashodaya’, which is ...
... to launch a new vaccination project to protect ... vaccination against pneumococcal meningitis will also be integrated ... meningitis is very serious," Diane McConnell, manager of ... die or be left with very severe after ...
... nitrogen-containing compounds that food producers use to cure meats may ... says a new study. // ,Previous studies have found ... study by Graham Barr at Columbia University Medical Center in ... the affect on lung function in humans, reported the online ...
... Mukesh Haikerwal, today urged all Australians to think about ... desire to donate organs.// ,Research published in the ... for transplant are harvested from only a fraction of ... found that, in many instances, organs are not donated ...
Cached Medicine News:Health News:800 Patients to be Dumped from Hospital Waiting Lists 2Health News:Action Against Doctors Harassing HIV/AIDS Patients 2Health News:AMA Urges Organ Donors to Speak Up 2
... Dehydroepiandrosterone sulfate (DHEA-S) is the sulfate ... and by enzymatic conversion of DHEA in ... major C19 steroid secreted by the adrenal ... and estrogen biosynthesis. DHEA possesses relatively weak ...
... Dehydroepiandrosterone sulfate (DHEA-S) is the sulfate ... and by enzymatic conversion of DHEA in ... major C19 steroid secreted by the adrenal ... and estrogen biosynthesis. DHEA possesses relatively weak ...
... sulfate ester of DHEA, derived from sulfated ... in adrenal and extradrenal tissues. DHEA is ... adrenal cortex, and is a precursor for ... weak androgenic activity, which for unsulfated DHEA ...
... kit is based on the competition principle ... of DHEA-S present in the sample and ... horse-radish peroxidase compete for the binding sites ... the wells. After one hour incubation the ...
Medicine Products: